HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Abrocitinib Consistent in Atopic Dermatitis Clearance Outcomes in Adolescents and Adults

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

Both continuous and reduced-dose regimens of abrocitinib provided similar efficacy and safety outcomes in adults and adolescents alike who initiated the drug for treatment of atopic dermatitis, according to new findings.

In post-hoc data presented at the Society of Dermatology Physician Assistants (SDPA) 2022 Annual Meeting in Miami, FL this week, a team of US investigators reported that a majority of adolescents and adults alike receiving open-label abrocitinib achieved skin clearance outcomes including Eczema Area Severity Index 75% (EASI 75) and Investigator’s Global Assessment (IGA) scores of 0 or 1.

Led by Prof. Carsten Flohr, head of pediatric and population-based dermatology research at St. John’s Institute of Dermatology in London, investigators conducted a post-hoc analysis of JADE REGIMEN, a phase 3 trial assessing Pfizer’s abrocitinib in patients ≥12 years old with moderate to severe atopic dermatitis. Patients in JADE REGIMEN who responded positively to a 12-week daily oral regimen of the therapy were randomized into a double-blind comparison of 200 mg or 100 mg abrocitinib, versus placebo, over 40 weeks.

The phase 3 trial additionally allowed for patients experiencing a disease-worsening flare to enter a 12-week rescue treatment regimen, including 200 mg abrocitinib plus topical therapy.

Flohr and colleagues sought to assess maintenance of response associated with continuous-dose or reduced-dose abrocitinib, or post-withdrawal reintroduction-dose abrocitinib.

Their patient population included 266 patients receiving 200 mg abrocitinib (47 adolescents; 219 adults), 265 receiving 100 mg abrocitinib (49 adolescents; 216 adults), and 267 receiving placebo (49 adolescents, 218 adults). Primary endpoint was a protocol-defined flare (loss of IGA response resulting in score of ≥2; loss of ≥50% of week 12 EASI response.

Regarding the efficacy of open-label 200 mg abrocitinib induction, investigators observed 59% of adolescent patients achieved both EASI 75 and IGA 0 or 1. Another 58% achieved Peak Pruritus Numerical Rating Scale scores of 4 (PP-NRS4). Adult patients with atopic dermatitis fared even better; 67% achieved both EASI-75 and IGA 0 or 1, and 71% achieved PP-NRS4.

However, adolescents treated with 200 mg abrocitinib were less likely to report a flare (15%) than adult patients on the same regimen (20%). Both adolescents and adults on 100 mg abrocitinib had a 43% probability of flare; patients on placebo in either age group had a ≥80% probability of flare.

Among patients to experience a flare during the rescue period of JADE REGIMEN, 29% and 25% of adolescents on abrocitinib 200 mg and 100 mg, respectively, recaptured EASI response; rates among adults in those treatment arms were 34% for each.

Regarding safety, abrocitinib 200 mg was associated with the greatest rate of treatment-emergent adverse events in both adolescents (68.1%) and adults (62.1%). However, serious adverse events with that treatment occurred in only 4.3% of adolescents and 5.0% of adults. The most common adverse events among each treatment arm and age group were nausea, acne, and herpes zoster infection.

“The efficacy and safety of abrocitinib induction and maintenance with continuous- or reduced-dose abrocitinib were similar between adults and adolescents,” investigators concluded. “More adults than adolescents achieved PP-NRS4 after induction.”

The study, “Efficacy and Safety of Abrocitinib Monotherapy in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE REGIMEN,” was presented at SDPA 2022.